NCT00318617终止不适用
A Two Part Study to Separately Evaluate the Effect of 4-week Treatment With GW501516X Relative to Placebo on Cardiac Energetics in a Randomized, Single-blind, Repeat Dose, Parallel Group Design in Healthy Male Subjects
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Energy-related chemicals and heart contraction, determined by MRI measurement of the heart.
研究概览
简要总结
The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, including levels of certain lipids (fats) and proteins in your blood. The data from this study may help researchers better understand the actions of this drug in the body and if this drug may be useful to treat patients with heart disease.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 40 Years(Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Energy-related chemicals and heart contraction, determined by MRI measurement of the heart.
次要结局
- Additional energy-related chemicals, determined by MRI measurement of the heart. Blood proteins. Safety of GW501516X.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)Exercise Induced AsthmaNCT00127166Organon and Co154
Unknown
4 期
Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus AlogliptinType 2 Diabetes MellitusNCT02426294Pusan National University Hospital154
终止
3 期
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic SeizuresSeizures Associated With EMASNCT05288283Jazz Pharmaceuticals3
已完成
3 期
Study Of Adults And Adolescents With Vasomotor RhinitisRhinitis, VasomotorNCT00117325GlaxoSmithKline352
已完成
3 期
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor RhinitisVasomotor RhinitisRhinitis, VasomotorNCT00118703GlaxoSmithKline350
